Insulet Tops S&P 500 Growth Chart for Q2 as It Gains Market Share in the Diabetes Space
Wells Fargo Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $240
Form 144 | Insulet(PODD.US) Insider Proposes to Sell 4.07 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 25, $Insulet(PODD.US)$ Insider Petrovic Shacey intends to sell 20,000 shares of its common stock on Jun 25, with a total market value of approximately $4.07 million. Sou
Insulet Points Its Insulin Pump at the Big Diabetes Market: Type 2 -- Barrons.com
Is weight loss medicine or stock market bomb? Eli Lilly and Co's new drug tirzepatide caused a sharp drop in sleep device stocks.
The recent clinical trial results of the new weight loss drug tirzepatide have not only caused a sensation in the medical community, but also stirred up waves in the stock market.
Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks
Tandem Diabetes, DexCom See Weakness Following ADA Conference
Jefferies Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $260
TD Cowen Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $264
Insulet Plans Label Expansion for Omnipod in Type 2 Diabetes
BofA Securities Maintains Insulet(PODD.US) With Buy Rating, Announces Target Price $255
Reported Earlier, Insulet's Omnipod 5 System Proves Effective in Type 2 Diabetes Management
Express News | Insulet’s Secure-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes
Express News | Insulet Corp - GLP-1 Initiation Does Not Impact the Continued Use of Insulin Among Current Insulin Users
Express News | Insulet Corp - More Than Half (55%) of People Who Adopt GLP-1 Therapy Discontinue Treatment Within 12 Months
Express News | Insulet Corp - Patients Who Stop GLP-1 Therapy Within the First 3 Months Are Even More Likely to Initiate Insulin Than Those Who Continue
Express News | Insulet Corp:Partnered With Optum Health Economics & Outcomes Research to Conduct Real-World Analysis Using Broad & Representative U.S. Claims Dataset
Express News | Insulet Corp - Patients Who Adopt GLP-1 Therapy Are Twice as Likely to Also Initiate Insulin Therapy Within the Ensuing 12 Months
$1000 Invested In Insulet 15 Years Ago Would Be Worth This Much Today
Insulet (PODD) Faces Increasing Competition